Clinatec Cea/Chuga
About Clinatec Cea/Chuga
Clinatec is a biomedical research center based at the Polygone Scientifique in Grenoble. Doctors, biologists and micro- and nanotechnology experts work side by side at the 6,000 m² facility. Around a hundred researchers and employees work at the center.
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Clinical Trials at Clinatec Cea/Chuga
During the past decade, Clinatec Cea/Chuga conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 0 clinical trials were completed, i.e. on
average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia
2007-03-01
2014-07-01
Completed
57
Prednisone or Dexamethasone in Newly Diagnosed, Previously Untreated Primary Immune Thrombocytopenic Purpura
2008-04-01
2016-02-01
Completed
150
Nilotinib and Imatinib Mesylate in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia
2009-02-09
2014-10-10
Completed
129
Clofarabine and Temsirolimus in Treating Older Patients With Relapsed or Refractory Acute Myeloid Leukemia
2008-12-01
2013-10-23
Completed
60
High-dose Chemotherapy and Stem Cell Transplantation, in Patients PET-2 Positive, After 2 Courses of ABVD and Comparison of RT Versus no RT in PET-2 Negative Patients
2008-09-01
2016-01-01
Completed
520
Study of Association of Arsenic Trioxide (ATO) and Ascorbic Acid in Myelodysplastic Syndromes
2005-09-01
2010-08-01
Terminated
55
Quality of Life and Symptoms in Patients With Newly Diagnosed Myelodysplastic Syndromes
2008-10-02
2021-02-01
Unknown status
927
Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of LR-CHOP21 for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma
2007-10-01
2012-01-01
Unknown status
49
Clinical Trials Sponsors and Collaborators
In terms of collaborators to trials, out of the total clinical trials conducted in "Clinatec Cea/Chuga"
#1 collaborator was "Commissariat A L'energie Atomique" with 3 trials as a collaborator and "Remedee SA" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were
collaborators in the rest 2 trials.
Clinical Trials Conditions at Clinatec Cea/Chuga
According to Clinical.Site data, the most researched conditions in "Clinatec Cea/Chuga" are
"Healthy Volunteers" (3 trials). Many other conditions were trialed in "Clinatec Cea/Chuga" in a lesser frequency.
Clinical Trials Intervention Types at Clinatec Cea/Chuga
Most popular intervention types in "Clinatec Cea/Chuga" are "Device" (2 trials) and "Behavioral" (1 trials). Other intervention types were less common.
The name of intervention was led by "Hypnosis" (1 trials), "Millimeter waves local exposure" (1 trials) and "VOP1k" (1 trials). Other intervention names were less common.
Clinical Trials Genders at Clinatec Cea/Chuga
The vast majority of trials in "Clinatec Cea/Chuga" are
2 trials for "All" genders and 1 trials for "Male" genders.
Clinical Trials Status at Clinatec Cea/Chuga
Currently, there are NaN active trials in "Clinatec Cea/Chuga".
undefined are not yet recruiting,
1 are recruiting,
undefined are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 2 completed trials in Clinatec Cea/Chuga,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in Clinatec Cea/Chuga, 0 "Phase 1"
clinical trials were conducted, 0 "Phase 2" clinical
trials and 0 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 3 trials that are defined as “Not Applicable".